Lead Product(s) : Fursultiamine
Therapeutic Area : Ophthalmology
Study Phase : Approved
Sponsor : Blackstone Life Sciences
Deal Size : $2,300.0 million
Deal Type : Divestment
Takeda to Divest its Japan Consumer Health Care Business Unit to Blackstone for JPY 242.0 Billion
Details : The portfolio to be divested includes a variety of over-the-counter medicines and health products. TCHC’s strong regional brands include Alinamin, and Benza.
Brand Name : Alinamin
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 24, 2020
Lead Product(s) : Fursultiamine
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Sponsor : Blackstone Life Sciences
Deal Size : $2,300.0 million
Deal Type : Divestment
LOOKING FOR A SUPPLIER?
Reset All
